Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles

Jenny G Parvani\textsuperscript{1,2} and Mark W Jackson\textsuperscript{2}

\textsuperscript{1}Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA
\textsuperscript{2}Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Abstract

Over the past decade, RNA interference (RNAi) has been ubiquitously utilized to study biological function \textit{in vitro}; however, limitations were associated with its utility \textit{in vivo}. More recently, small interfering RNA (siRNA) nanoparticles with improved biocompatibility have gained prevalence as a potential therapeutic option for the treatment of various diseases. The adaptability of siRNA nanoparticles enables the delivery of virtually any siRNA, which is especially advantageous for therapeutic applications in heterogeneous diseases that lack unifying molecular features, such as triple-negative breast cancer (TNBC). TNBC is an aggressive subtype of breast cancer that is stratified by the lack of estrogen receptor/progesterone receptor expression and HER2 amplification. There are currently no FDA-approved targeted therapies for the treatment of TNBCs, making cytotoxic chemotherapy the only treatment option available to these patients. In this review, we outline the current status of siRNA nanoparticles in clinical trials for cancer treatment and discuss the promising preclinical approaches that have utilized siRNA nanoparticles for TNBC treatment. Next, we address TNBC subtype-specific therapeutic interventions and highlight where and how siRNA nanoparticles fit into these strategies. Lastly, we point out ongoing challenges in the field of siRNA nanoparticle research that, if addressed, would significantly improve the efficacy of siRNA nanoparticles as a therapeutic option for cancer treatment.

Introduction

RNA interference (RNAi) is a process where small double-stranded RNAs consisting of approximately 22nt are utilized to repress gene expression. These effects were first observed in nematode worms in 1998, where expression of \textit{par-1} mRNA was temporarily depleted after the introduction of double-stranded small interfering RNA (siRNA) (Fakhr \textit{et al.} 2016, Young \textit{et al.} 2016). Further studies identified additional molecular players in the RNAi machinery, including Dicer and the RNA-induced silencing complex (RISC) (Kobayashi & Tomari 2016). Upon uptake of the double-stranded siRNA, Dicer unwinds and cleaves the sense strand (Fig. 1). The antisense strand then acts as a guide for the recognition of complementary mRNAs, and the RISC complex forms (Fig. 1). If the antisense strand is perfectly complement to the mRNA, the mRNA is cleaved by argonaute 2 (Ago2), the catalytic subunit of the RISC complex (Azlan \textit{et al.} 2016, Fakhr \textit{et al.} 2016). Limited complementarity to the target mRNA leads to translational repression, a function that is associated with micro RNAs (miRNAs) (Young \textit{et al.} 2016). Since its
discovery, siRNAs have been widely utilized in vitro to interrogate various cell and molecular biology questions. However, siRNA use in vivo has been limited by its (1) labile nature, (2) anionic properties and (3) proclivity to raise immune responses. Therefore the use of siRNA in a therapeutic setting requires further shielding of the siRNA to address these challenges.

One method of overcoming these limitations is to encapsulate the naked siRNA within nanoparticles. Nanoparticles can be made from various materials (Wang et al. 2010, Jeong et al. 2011). Two main categories consist of organic and inorganic nanoparticles (Miele et al. 2012, Young et al. 2016). Organic nanoparticles are composed of materials that either occur naturally or from a synthesized source (Lopez-Davila et al. 2012, Young et al. 2016). These include but are not limited to (1) lipid nanoparticles such as micelles and liposomes and (2) polymer-based nanoparticles such as dendrimers and cyclodextrin nanoparticles (Fig. 2) (Wen & Steinmetz 2016, Young et al. 2016). Inorganic nanoparticles typically consist of non-biodegradable biomaterials including metals, metal oxides and other carbon materials (Young et al. 2016). Additional complex, hybrid nanoparticles that consist of both organic and inorganic biomaterials also exist. For readers desiring a more in depth understanding of nanoparticle biomaterials as well as advantages and disadvantages associated with each, we recommend several recent comprehensive reviews (Jeong et al. 2011, Miele et al. 2012, Young et al. 2016).

Nanoparticle size and surface charge significantly affect circulation time; therefore, a number of parameters and modifications are adapted to enhance nanoparticle longevity. Three major modes of nanoparticle clearance in vivo include urine excretion through the renal filtration system, biliary excretion through the liver filtration system and uptake by phagocytic cells of the immune system (Longmire et al. 2008, 2011). Importantly, nanoparticle accumulation and clearance by the kidneys, liver and blood are significantly dependent on the particle size and material (De Jong et al. 2008, Longmire et al. 2011). First, the glomerulus, or renal filtration functional unit, is capable of excreting nanoparticles with minimal catabolism of the particles. Particles that are excreted by glomerular filtration are typically 6 nM or smaller in diameter (Longmire et al. 2008, 2011, Lorenzer et al. 2015). In addition to size, particle surface charge can also affect the efficiency of renal excretion. Previous studies demonstrate that among particles that are similar in size, positively charged particles are mostly effectively excreted, which is followed by neutral particles and lastly by negatively charged particles (Deen et al. 2001). These differences in charge-selective excretion is partly attributed to the negatively charged glomerular capillary wall that preferentially attracts positively charged particles.
Particles that escape renal excretion may be cleared by the liver. Within the liver, nanoparticles can be internalized by endothelial cells, hepatocytes and Kupffer cells, and different nanomaterials are selectively and differentially internalized by these cells (Heine et al. 2014, Bargheer et al. 2015). Hepatocyte and Kupffer cells further mediate the enzymatic breakdown of the engulfed particle, which range between 10 and 20 nM in size (Longmire et al. 2008, 2011). Kupffer cells rely solely on intracellular breakdown of the engulfed material, whereas hepatocytes-mediated nanoparticle clearance also involves the excretion through bile (Longmire et al. 2008, 2011). Moreover, nanoparticles in circulation are also opsonized or tagged by serum proteins for phagocytosis by immune cells. Opsonization is affected by various nanoparticle characteristics such as hydrophobicity, size and charge (Alexis et al. 2008, Lim et al. 2008). Nanoparticles that are greater than 200 nM are readily cleared by phagocytic immune cells (Lorenzer et al. 2015). In addition to size and charge, several additional factors also affect nanoparticle circulation time.

Surface modification with polyethylene glycol (PEG), a biocompatible polymer, has also been demonstrated to significantly increase circulation time by (1) reducing charge-based interactions with the glomerular capillaries and (2) shielding nanoparticles from phagocytic cells (Li & Szoka 2007, Jekerst et al. 2011). The net effect of PEGylation is also associated with decreased cellular uptake of nanoparticles; therefore, additional modifications of the nanoparticles are required to improve accumulation within tumor cell. PEGylated nanoparticles are coated with a number of targeting ligands whose receptors are highly expressed on tumor cells to promote receptor-mediated endocytosis. Commonly utilized targeting ligands are summarized in Table 1 (Nahta & Esteva 2006, Cao et al. 2011, Deng et al. 2013, Seitz et al. 2013, Feng et al. 2014, Necela et al. 2015, Parvani et al. 2015, Arosio & Casagrande 2016, Bakrania et al. 2016, Gu et al. 2016, Xu et al. 2016). Importantly, these strategies significantly improve nanoparticle uptake by tumor cells. Various other factors including nanoparticle shape (Geng et al. 2007, Sadekar et al. 2011), flexibility (Kobayashi et al. 2001, Ogawa et al. 2010), surface coating (Heine et al. 2014, Bargheer et al. 2015) and cargo (Zintchenko et al. 2008, Scholz & Wagner 2012) may all play a role in nanoparticle stability and life span.

There are several advantages to using siRNA nanoparticle platforms as a therapeutic strategy. Recent advances in next-generation high-throughput sequencing have revealed extraordinary genetic complexity and heterogeneity in cancer models (Hoelder et al. 2012). Because siRNAs are readily synthesized and can be optimized to maximize gene silencing (Fakhr et al. 2016), siRNA nanoparticles can be easily adapted to silence virtually any gene in mammalian cells. Various siRNA design software that enable the optimization of siRNA length, specificity and nucleotide content based on a number of criteria are available online.
These tools offer a quick way to focus screening of numerous siRNAs for numerous genes, which contrasts time-consuming traditional ways of searching for small molecule inhibitors against a target (Hoelder et al. 2012). siRNA nanoparticles are also equipped to silence splice variants and transcription factors, which were previously thought of as ‘undruggable’ (Johnston & Carroll 2015). Not surprisingly, several siRNA nanoparticles are currently being tested in clinical trials as cancer therapeutics.

### Clinical application of siRNA nanoparticles in cancer treatment

Preclinical studies in various different tumor models have demonstrated siRNA nanoparticles to be effective in inhibiting tumor growth (Parvani et al. 2015, Su et al. 2015, Zhang et al. 2016), metastasis (Parvani et al. 2015, Zhao et al. 2015), angiogenesis (Liu et al. 2015, Malamas et al. 2016) and drug resistance (Deng et al. 2013, Zhang et al. 2016). These studies have paved the way for various ongoing clinical trials, which are summarized in Table 2. The efficacies of several different siRNA nanoparticles are currently being evaluated for safety and pharmacokinetics in phase 1 clinical trials, and among these, 4 studies have been completed and 1 has been terminated.

Atu027 is a lipid nanoparticle with a particle diameter of about 120 nm (Santel et al. 2006), delivering siRNA against protein kinase N3 (PKN3), a downstream effector of the PI3 kinase pathway, for the treatment of various solid tumors (Schultheis et al. 2014). In preclinical mouse models, silencing PKN3 is associated with decreased tumor growth and metastases (Aleku et al. 2008). The phase 1 clinical trial evaluating Atu027 consisted of 34 treatment-naïve patients harboring a variety of advanced

<table>
<thead>
<tr>
<th>Clinical trial phase</th>
<th>Drug name</th>
<th>Nanoparticle material</th>
<th>Targeting strategy</th>
<th>Target</th>
<th>Disease</th>
<th>Company</th>
<th>Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Atu027</td>
<td>Lipid nanoparticle</td>
<td>None</td>
<td>Protein kinase N3</td>
<td>Solid tumors</td>
<td>Silence Therapeutics</td>
<td>Completed</td>
</tr>
<tr>
<td>I</td>
<td>ALN-VSP</td>
<td>Lipid nanoparticle</td>
<td>None</td>
<td>VEGF and KSP</td>
<td>Solid tumors with liver involvement</td>
<td>Alnylam</td>
<td>Completed</td>
</tr>
<tr>
<td>I</td>
<td>TKM 80301</td>
<td>Lipid nanoparticle</td>
<td>None</td>
<td>Polo-like kinase 1</td>
<td>Primary or secondary liver cancer</td>
<td>NCI</td>
<td>Completed</td>
</tr>
<tr>
<td>I</td>
<td>CALAA-01</td>
<td>Polymer (cyclodextrin) nanoparticle</td>
<td>Transferrin</td>
<td>RRM2</td>
<td>Solid tumors</td>
<td>Calando</td>
<td>Terminated</td>
</tr>
<tr>
<td>I</td>
<td>siG12D LODER</td>
<td>Polymer (PLGA) nanoparticle</td>
<td>Implanted into tumor</td>
<td>KRASG12D</td>
<td>Pancreatic ductal adenocarcinoma</td>
<td>Silenseed Ltd.</td>
<td>Completed</td>
</tr>
<tr>
<td>I</td>
<td>siRNA-EphA2-DOPC</td>
<td>Lipid nanoparticle</td>
<td>None</td>
<td>EphA2</td>
<td>Solid tumors</td>
<td>MD Anderson Cancer Ctr</td>
<td>Not yet open</td>
</tr>
<tr>
<td>II</td>
<td>siG12D LODER</td>
<td>Polymer nanoparticle</td>
<td>Implanted into tumor</td>
<td>KRASG12D</td>
<td>Pancreatic ductal adenocarcinoma</td>
<td>Silenseed Ltd.</td>
<td>Recruiting</td>
</tr>
<tr>
<td>I</td>
<td>TKM 80301</td>
<td>Lipid nanoparticle</td>
<td>None</td>
<td>Polo-like kinase 1</td>
<td>Solid tumors</td>
<td>Tekmira</td>
<td>Not yet open</td>
</tr>
</tbody>
</table>
solid tumors (Schultheis et al. 2014). These patients were intravenously infused with 10 escalating doses of Atu027, and results indicated that (1) these nanoparticles are well tolerated in patients up to 0.336 mg/kg and (2) 41% of patients exhibited stable disease for at least 8 weeks (Schultheis et al. 2014). These promising results have laid a solid foundation for additional clinical trials.

ALN-VSP is a lipid nanoparticle with a particle diameter of 80–100 nm, delivering siRNA against vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP) at a 1:1 molar ratio for the treatment of liver cancers (Tabernero et al. 2013). VEGF is a growth factor that is essential for angiogenesis, endothelial cell permeability and general preservation of vessel function (Gopal et al. 2016). KSP is a microtubule-interacting protein that is involved in the regulation of mitosis and apoptosis (Naymagon & Abdul-Hay 2016). In a phase 1 clinical trial, patients received intravenous injections of ALN-VSP doses that ranged from 0.4 to 1.0 mg/kg (Tabernero et al. 2013). Tumor biopsies from 12 patients indicated significant accumulation of the siRNA and target mRNA cleavage within the tumor (Tabernero et al. 2013). Overall, ALN-VSP was well tolerated in patients and exhibited antitumor activity, including the complete regression of liver metastases originating from a primary endometrial tumor. Further development of ALN-VSP is expected.

TKM-080301 is a lipid nanoparticle-delivering siRNA against polo-like kinase 1 (PLK1) (Liu 2015). PLK1 is a serine–threonine kinase that regulates mitosis, DNA replication and cellular stress response (Liu 2015). Elevated expression of PLK1 has been observed in various cancers, including but not limited to breast, colorectal, prostate and head and neck cancers (Takai et al. 2005). Preclinical studies have demonstrated that depletion of PLK1 expression preferentially inhibits the survival of tumor cells in xenograft models (Spankuch et al. 2004, Guan et al. 2005, Liu 2015). A phase 1 trial evaluating the pharmacodynamics of TKM-080301 in patients harboring lymphoma or advanced solid tumors has been completed; however, the trial report is currently unavailable.

CALAA-01 is a cyclodextrin-based polymeric nanoparticle with a particle diameter ranging from 60 to 150 nm, delivering siRNA against the ribonucleotide reductase M2 subunit (RRM2) for the treatment of a variety of solid tumors (Zuckerman et al. 2014). RRM2 is essential for the regulation of nucleotide synthesis, and its expression is frequently upregulated in many cancers (Furuta et al. 2010). In a phase 1a clinical trial, 15 patients were treated with CALAA-01 delivering between 3 and 30 mg/m² of siRNA (Zuckerman et al. 2014). No initial dose-limiting toxicities were observed; however, approximately two years after initial treatment, two patients receiving the maximum dose experienced toxicity symptoms. The clinical protocol was subsequently modified to administer patients with a lower initial dose of CALAA-01, with the hypothesis that reduced initial exposure may dampen immunogenicity that was associated with toxicity (Zuckerman et al. 2014). However, the study was terminated when two out of five patients enrolled in the phase 1b clinical trial developed dose-limiting toxicities. The scientific report documenting the termination of the trial has not been published; however, preliminary results suggest that the toxicity of CALAA-01 is associated with the delivery vehicle rather than the siRNA (Zuckerman et al. 2014). It is proposed that these toxicities may be neutralized by alternative purification of CALAA-01 after its preparation (Zuckerman et al. 2014).

siG12D LODER is a biodegradable and implantable cylindrical rod (diameter: 0.9 mm; length 4 mm) that is composed of a copolymer of poly (lactic-co-glycolic) acid (PLGA) (Ramt et al. 2016). This polymer matrix encapsulates anti-KRAS(12G > D) siRNA (siG12D) to enable sustained local release of siG12D for the treatment of locally advanced pancreatic cancer (Zorde Khvalevský et al. 2013, Golan et al. 2015, Ramot et al. 2016). Greater than 90% of pancreatic ductal adenocarcinomas (PDACs) harbor mutated KRAS, and the majority of these are activating mutations occurring within codon 12. The most common codon 12-activating KRAS mutations include 12G > D (61%), 12G > R (18%) and 12G > V (17%) (Rachakonda et al. 2013). Importantly, previous studies have demonstrated that PDAC cells are addicted to mutant KRAS, such that a reduction in KRAS expression is associated with reduced cell viability (Singh et al. 2009). These findings have set the foundation to silence mutant KRAS as a therapeutic strategy for PDAC treatment. The phase 1 clinical trial evaluating siG12D LODER consisted of 15 pancreatic cancer patients, divided into 3 dose cohorts. The siG12D LODER implant was inserted into the PDAC lesion via standard biopsy procedures for sustained release of siG12D for 4 months with concomitant weekly intravenous infusion of chemotherapy (Golan et al. 2015). Results indicate that the implant was safe and well tolerated, with transient adverse effects (Golan et al. 2015). Preliminary CT scans revealed that the majority of patients had stable disease, whereas 2 patients exhibited partial response (Golan et al. 2015). Moreover, 70% of patients experienced a decrease in the pancreatic tumor marker, CA19-9 (Swords et al. 2016). A phase 2 clinical trial consisting of a larger cohort of patients to evaluate
the response rate of advanced pancreatic cancer patients treated with the chemotherapy and siG12D LODER is underway.

These clinical studies have laid a solid foundation of evaluating siRNA nanoparticles in various solid tumors, and additional trials are currently recruiting patients (Table 2). Lipid nanoparticles appear to be more widely tested than polymer nanoparticles in clinical trials; however, preliminary results from completed trials have demonstrated safety and efficacy using both nanomaterials. Successful evaluation of siRNA nanoparticles could potentially lead to the application of this powerful technology for the future treatment of various cancers, including breast cancer.

**Triple-negative breast cancer (TNBC) and current standard treatments**

Breast cancer is the most common cancer among women, with an estimated 246,660 newly diagnosed cases in the United States in 2016 (ACS 2016). Importantly, breast cancer is not a single disease; instead, it is clinically subcategorized into three major subtypes, which include hormone receptor-positive, HER2-positive and triple-negative breast cancers (TNBCs). This classification system has significant therapeutic and prognostic implications.

As its name suggests, TNBCs are those that lack estrogen receptor (ER) expression, progesterone receptor (PR) expression and HER2 amplification as determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses. There are currently no biomarkers that positively define TNBCs; therefore, TNBCs have been stratified by excluding tumors containing greater than 10% positivity in ER, PR and HER2. In 2010, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated their guidelines for defining ER- and PR-negative tumors as those having <1% positivity to better accommodate patients who may benefit from endocrine- and HER2-targeted therapies (Hammond et al. 2010). TNBCs are typically more clinically aggressive and occur more frequently in younger women and women of African and Hispanic ancestry (Alluri & Newman 2014). Moreover, patients with TNBC are more likely to die from their disease within 5 years of diagnosis in comparison to patients with non-TNBC (Dent et al. 2007).

Unlike patients harboring luminal and HER2 breast cancers, who benefit from estrogen receptor and HER2 antagonists, there are no FDA-approved targeted therapies for the treatment of TNBC. Current standard local therapies include surgery and radiotherapy, whereas systemic therapy includes the use of cytotoxic chemotherapy (Yagata et al. 2011). TNBC lesions are typically unifocal, making breast conserving therapy a plausible option (Yagata et al. 2011). Regional and locoregional recurrences are typically higher in TNBC than those in non-TNBC; however, radiation therapy after surgery has been demonstrated to decrease recurrence (Kyndt et al. 2008, Voduc et al. 2010). Systemic therapy includes the use of taxane-anthracycline regimens that most TNBC patients initially respond to (Chacon & Costanzo 2010, Stover & Winer 2015); however, chemosensitivity is often short-lived and the majority of patients relapse and succumb to metastatic disease (O’Reilly et al. 2015). Additionally, in comparison to patients harboring non-TNBC, those harboring TNBC also typically experience shorter average time to local recurrence (2.8 years vs 4.2 years), shorter mean time to distant recurrence (2.6 years vs 5 years) and increased rate of distant recurrence (33.9% vs 20.4%) (Dent et al. 2007). Because of these ongoing challenges associated with TNBC treatment, various novel targeted treatment approaches are currently being explored, including siRNA nanoparticles.

**Preclinical studies of siRNA nanoparticles in the treatment of TNBCs**

The clinical successes of siRNA nanoparticles for the treatment of various solid cancers have paved the way for its application in TNBC. Several recent preclinical studies have explored different siRNA delivery vehicles to silence an assortment of target genes that are associated with poor prognosis in TNBC. These studies have largely focused on siRNA nanoparticle application in 3 major areas for the treatment of TNBCs: inhibiting components of the cell cycle, inhibiting epithelial–mesenchymal transition (EMT) and improving chemotherapeutic efficacy.

**siRNA silencing of cell cycle regulators**

FOXM1 is a transcription factor that functions as a master regulator of the cell cycle by inducing G1→S and G2→M transitions (Saba et al. 2016). Notably, FOXM1 is overexpressed in many cancers, which has been correlated to metastasis and disease progression (Saba et al. 2016). In a recent study, Hamurcu and coworkers demonstrated that FOXM1 is overexpressed in numerous TNBC cell lines and that depletion of FOXM1 expression inhibits cyclin D1 expression and SRC (Y416) and ERK activation (Hamurcu et al. 2016). Functionally, these changes
coalesced to reduce colony formation, proliferation, invasion and migration (Hamurcu et al. 2016). Traditionally, transcription factors have commonly been thought of as ‘undruggable’ due to their lack of enzymatic activities (Yan & Higgins 2013, Johnston & Carroll 2015); however, these limitations are lifted by siRNA nanoparticles. Two weeks after nude mice were engrafted with MDA-MB-231 tumors, they were administered with control and FOXM1 targeting siRNA encapsulated within liposomal lipid nanoparticles at 0.3 mg/kg weekly (Hamurcu et al. 2016). Results demonstrated significant reduction of FOXM1 expression in the primary tumor, which was associated with decreased primary tumor burden (Fig. 3A) (Hamurcu et al. 2016). Future studies should evaluate tumor recurrence after withdrawal of FOXM1 siRNA nanoparticles.

In another study, cyclin-dependent kinase 11 (CDK11) and casein kinase II (CK2) were evaluated as potential therapeutic targets for the treatment of TNBCs (Kren et al. 2015). CDK11 and CK2 are two well-established molecular players that mediate cancer cell growth and survival. CDK11 is an atypical CDK that functions in mitosis, transcription and RNA splicing, and its elevated expression is observed in TNBCs (Zhou et al. 2016). CK2 is a Ser/Thr protein kinase that phosphorylates numerous substrates that function in cell biology processes such as transcription, cell cycle regulation, apoptosis and others (Meggio & Pinna 2003). Elevated expression of CK2 in human breast cancers correlates with metastasis (Giusiano et al. 2011). Kren and coworkers encapsulated CDK11 and CK2 siRNAs into polyamine-based micelles that are coated with tenfibgen (TBG) protein. TBG is specifically recognized by tenasin C, a receptor that is highly expressed in breast cancer stroma (Guttery et al. 2010). Control TBG-coated nanoparticles or those encapsulating siRNAs against CDK11 were administered via intravenous injection at a dose of 0.01 mg/kg, every 3–4 days for 10 days. Mice receiving nanoparticles that delivered CDK11 siRNAs harbored significantly smaller primary tumors (Fig. 3A) (Kren et al. 2015). Future studies should evaluate the changes in metastatic potential of the xenografted tumors in response to nanoparticle administration.

In a third study, Liu and coworkers utilized siRNA nanoparticles to target CDK1, a cyclin-dependent kinase, that has recently been demonstrated to be synthetic lethal in TNBC models harboring elevated Myc expression (Horiuchi et al. 2012). MYC is an oncprotein that is frequently overexpressed in TNBCs. Directly targeting MYC as a therapeutic strategy has not come to fruition because (1) designing a small-molecule inhibitor to disrupt protein–protein or protein–DNA interactions necessary for MYC function has proven to be challenging (Horiuchi et al. 2014) and (2) MYC expression is essential for regeneration and maintenance of stem cells in the bone marrow, skin and gastrointestinal tract (Soucek et al. 2008). Using a cationic lipid-based PEG–PLA nanoparticle system, Liu and coworkers delivered CDK1-specific siRNA to TNBC cells harboring elevated MYC expression and observed decreased Myc expression that is accompanied by (1) decreased cell viability, (2) decreased colony formation and (3) increased apoptosis in vitro (Liu et al. 2014). In vivo, administering siCDK1 nanoparticles culminated
in significant reduction of primary tumor burden (Fig. 3A). Importantly, no significant changes in body weight and inflammatory cytokines were noted, indicating no major toxicities (Liu et al. 2014). As with previous studies, changes in metastatic potential were not evaluated.

In summary, various groups have demonstrated the effectiveness of siRNA nanoparticles at reducing primary tumor burden by targeting key cell cycle regulators. Insignificant changes in body weight and immune cytokine production were observed, which suggest that these delivery platforms are safe and well tolerated. However, as most breast cancer patients undergo surgery to remove the primary tumor, and metastasis is ultimately the factor associated with patient mortality, future studies need to evaluate how tumor recurrence and metastatic potential can be targeted by these siRNA nanoparticles.

siRNA silencing inducers of epithelial–mesenchymal transition

Epithelial–mesenchymal transition (EMT) is a normal physiological program that occurs during development, fibrosis and wound healing (Taylor et al. 2010). Aberrant activation of EMT engenders its pathophysiological characteristics associated with cancer (Taylor et al. 2010). Over the past decade, the effects of EMT have been expanded to include alterations in cell motility and invasion, acquisition of stem-like characteristics, resistance to chemotherapy and remodeling of the tumor microenvironment (Morrison et al. 2013). Given its salient role in malignancy, attention has turned to targeting EMT for the treatment of TNBCs.

Various transcription factors, such as members of the TWIST, SNAIL and ZEB families, have previously been characterized as master regulators of EMT (Taylor et al. 2010). Recently, Finlay and coworkers utilized an amphiphilic dendrimer to silence TWIST1 in TNBC cells (Finlay et al. 2015). The authors verified target cell uptake of the dendriplexes that mediated significant reduction of TWIST1 expression in SUM1315 TNBC cells (Finlay et al. 2015). In vitro, the functional consequences of silencing TWIST1 coalesced to reduce (1) expression of the EMT markers, N-cadherin and vimentin and (2) cancer cell migration and invasion (Fig. 3B) (Finlay et al. 2015). Furthermore, the authors confirmed that intratumoral injection of the dendriplexes delivering a fluorescent siRNA effectively induced siRNA uptake by tumor cells and that the fluorescent siRNA was only minimally internalized by cells in other organs. Future studies will need to characterize the in vivo effects of dendriplexes delivering TWIST1 siRNA to TNBC xenograft models.

EMT can also be induced in response to microenvironmental regulators. β3 integrin is a transmembrane protein that functions as the vitronectin and fibronectin receptor when it is homodimerized to αv integrin (Parvani et al. 2013, Missirlis et al. 2016). Previous studies have demonstrated that β3 integrin plays essential roles in transforming growth factor-beta (TGF-β)-mediated EMT (Galliher & Schiemann 2006, Parvani et al. 2013). Using a lipid-based siRNA carrier called ECO, Parvani and coworkers demonstrated that a single 4-hour dose of ECO/siβ3 lipid nanoparticles was sufficient to sustain prolonged silencing of β3 integrin in both mouse and human breast cancer cell lines for up to 7 days (Parvani et al. 2015). Furthermore, silencing β3 integrin in vitro inhibits EMT in TNBC cell lines, in part by the upregulation of epithelial markers, cytokeratin (CK) 19 and E-cadherin and downregulation of mesenchymal markers, N-cadherin and PAI1 (Fig. 3B) (Parvani et al. 2015). β3 integrin depletion also reduces proliferation and invasion in 2D cultures and inhibits 3D organotypic outgrowth. To improve the circulation time and tumor cell uptake, the ECO/siβ3 lipid nanoparticles were further modified with PEG, which is conjugated to an RGD peptide that is recognized by β3 integrin (Iyer et al. 2013). When administered to nude mice engrafted with MDA-MB-231 tumors, RGD-ECO/siβ3 lipid nanoparticles effectively decreased primary tumor burden, primary tumor recurrence and metastatic tumor burden (Parvani et al. 2015). The authors verified decreased β3 integrin expression in primary tumors that were surgically removed, and H&E staining of control and RGD-ECO/siβ3-treated tumors indicate reduced tumor-associated vasculature in the experimental group (Parvani et al. 2015).

In summary, these studies demonstrated that targeting EMT-inducing factors is an effective way to reduce tumorigenicity of TNBC. Because of the salient role EMT plays in mediating stem-like characteristics and drug resistance, future studies should explore how silencing EMT-inducing factors would affect these phenotypes. Future studies also need to determine which combination of EMT transcription factor, if silenced by siRNA nanoparticles, would be most efficacious at inhibiting TNBC disease progression.

Improving chemotherapeutic efficacy

In 1995, the FDA approved its first nanodrug, Doxil, a PEGylated liposomal formulation of doxorubicin.
(Fajardo-Ortiz et al. 2014, Marchal et al. 2015). Liposomal encapsulation of doxorubicin prevents breakdown of the drug before reaching tumor cells. The effects of this are twofold: (1) increased cytotoxic effect of the drug is achieved as a greater amount of the drug is reaching tumor cells and (2) decreased side effects of the drug is also achieved as normal cells are exposed to the active drug less frequently (Lao et al. 2013). PEGylation of these liposomal formulations further extends circulation time that increases the propensity of the drug to reach tumor cells (Khan et al. 2015). These improvements have translated to clinical success, and Doxil is currently utilized to treat recurrent breast cancer. Despite these successes, limitations associated with Doxil remain. First, although the PEGylated formulation is associated with increased circulation time, the presence of the PEG moiety also creates steric hindrance that limits tumor cell uptake (Khan et al. 2015). Furthermore, doxorubicin inherently exhibits high affinity for extracellular matrix proteins, which further limits tumor cell uptake of the drug (Khan et al. 2015). These limitations are indicative that further modifications of Doxil are required for its optimal use. Deng and coworkers address these deficiencies by constructing a dual-siRNA-chemotherapy co-delivery system, where an siRNA film against multidrug-resistant protein 1 (MRP1) was built around a chemotherapy-loaded nanoparticle core (Fig. 3C). Furthermore, these nanoparticles were coated with hyaluronic acid (HA), which has previously been demonstrated to (1) enhance in vivo stability and (2) mediate active uptake by CD44, a receptor that is highly expressed on some TNBC cells (Deng et al. 2013). Nude mice engrafted with MDA-MB-468 tumors were treated with this elegant system every 5 days for 15 days, with each dose of the experimental group consisting of 1 mg/kg doxorubicin and 1 mg/kg MRP1 siRNA. The control group delivering MRP1 siRNA only did not exhibit tumor inhibitory effects. The experimental group delivering both the siRNA and doxorubicin reduced tumor volume by (1) 8-fold in comparison to vehicle-treated group and (2) by 4-fold in comparison to the control group delivering doxorubicin only (Deng et al. 2013).

Another group combined photothermal therapy (PTT) with gene therapy and chemotherapy (Su et al. 2015). This ‘triple punch’ nanoparticle delivers paclitaxel, siRNA against survivin, a gene associated with poor prognosis in TNBCs and indocyanine green (ICG), a PTT agent that has been approved by the FDA as a clinical imaging agent (Fig. 3C) (Su et al. 2015). In response to near-infrared (NIR) laser irradiation, hyperthermia produced by ICG mediates deformation of the nanoparticle core structure, which induces the release of paclitaxel and survivin siRNA. MDA-MB-231 tumors were engrafted onto nude mice and treated with 2 doses of triple therapy nanoparticles (NP-IPS) that contain 0.32 µmol/kg of ICG, 0.54 µmol/kg of paclitaxel and 1.5 mg/kg of survivin siRNA within 30 days (Su et al. 2015). In comparison to control groups receiving mono or dual therapies, mice receiving NP-IPS had complete growth inhibition of MDA-MB-231 xenograft tumors, without any indication of tumor recurrence. Evaluation of post-mortem histopathology of various organ systems indicates no injury or damage in mice receiving nanoparticles.

**TNBC subtype-specific therapeutic strategies: what are the limitations and how do siRNA nanoparticles fit in?**

Previous studies have further subcategorized TNBCs into six distinct transcriptional subtypes (Lehmann et al. 2011). These include two basal-like (BL1 and BL2) subtypes, a mesenchymal (M) subtype, a luminal androgen receptor (LAR) subtype, a mesenchymal stem-like (MSL) subtype and an immunomodulatory (IM) subtype (Lehmann et al. 2011). Each of these subtypes preferentially respond to different therapeutic agents. Although current standard clinical practice for TNBC treatment do not take these 6 subtypes into account, efforts have been made in ongoing clinical trials to treat patients based on specific molecular subsets (Lehmann et al. 2015). In this section, we explore how siRNA nanoparticles can be utilized to enhance subtype-specific TNBC treatments.

**Basal-like TNBCs and cisplatin**

The BL1 and BL2 subtypes are enriched for cell cycle and DNA damage response genes and are preferentially sensitive to cisplatin (Lehmann et al. 2011). Cisplatin is a platinum-containing chemotherapy that exerts its therapeutic effects by binding to DNA, causing DNA cross-linking, which leads to apoptosis (Apps et al. 2015). Interestingly, BL breast cancers have striking similarities to BRCA1-mutated breast cancers, which exhibit defective DNA homologous recombination. Both BL breast cancers and BRCA1-mutated breast cancers are (1) diagnosed in younger women, have poor prognosis and high mitotic index; (2) characterized by genomic instability and (3) preferentially respond to DNA damaging agents as demonstrated in xenograft mouse models and in clinical trials (Lehmann et al. 2011, Toft & Cryns 2011, Isakoff et al. 2015). Gene expression analysis indicates that
there is a subset of BL breast cancers that harbor BRCA1 mutations, whereas other BL breast cancers retain wild-type (WT) BRCA1 (Prat et al. 2014). Those that retain WT BRCA1 typically contain mutations or alterations in other molecular players of the homologous recombination pathway, which enhances chemosensitivity to platinum agents (Toft & Cryns 2011, Prat et al. 2014, Baker et al. 2016). Although BL TNBCs are more responsive to cisplatin, resistance mechanisms have been documented. Mechanisms of cisplatin resistance include secondary reversion mutations in BRCA1/2 that circumvent the therapeutic effects of cisplatin (Dhillon et al. 2011). Utilizing siRNA nanoparticles to eliminate BRCA1/2 expression in combination with cisplatin may eliminate these resistant mechanisms (Table 3). Should a reversion mutation in BRCA1/2 arise in a region that overlaps with the chosen BRCA1/2 siRNA, alternative siRNA sequences against BRCA1/2 may be utilized. Because functional BRCA1 is essential for DNA damage repair in normal cells, it is imperative that the siRNA delivery platform utilized to deliver BRCA1/2 siRNA exhibit tumor cell-specific uptake to reduce complications from off-target effects in other organ systems.

Mesenchymal TNBCs and PI3K/mTOR inhibitors

The mesenchymal subtype of TNBCs harbor elevated growth factor signaling and proteins involved in EMT and representative cell lines preferentially respond to PI3K/mTOR inhibitors (Lehmann et al. 2011). Clinical trials testing the combination of mTOR inhibitors with a variety of chemotherapies and EGFR-family-targeted agents are under way (Paplomata & O’Regan 2014, Massihnia et al. 2016). Similarly, a phase 2 clinical trial evaluating the efficacy of BKM120, a pan class 1 PI3K inhibitor, is ongoing (Mohamed et al. 2013, Paplomata & O’Regan 2014). Within the past 2 decades, various modes of PI3K/mTOR and RAS/ERK signaling crosstalk have been elucidated (Mendoza et al. 2011), and efforts to utilize small molecule inhibitors against both pathways in combination are also being tested in phase 1 clinical trials (Jokinen & Koivunen 2015). Preliminary studies have been disappointing, with a combined overall response rate of 4.7%, suggesting that improved strategies to inhibiting these pathways are necessary (Jokinen & Koivunen 2015).

Class 1 PI3K, consists of P110α, P110β and P110γ catalytic kinases that exist as heterodimers. Previous studies utilizing several cancer cell lines have demonstrated that small molecule inhibitors against P110β were ineffective, whereas an siRNA approach that silences P110β effectively inhibits proliferation (Weiss et al. 2007, Mendoza et al. 2011). Mechanistically, small molecule inhibition of P110β inhibits its kinase activity, which does not alter the expression levels of the PI3K regulatory subunit, P85. However, silencing P110β with siRNAs disables its scaffolding functions leading to decreased P85 expression. Alteration of the P85-to-P110β ratio induces negative feedback loops that coalesce to inhibit proliferation (Fan et al. 2006). These results suggest that siRNA nanoparticle silencing of catalytic PI3K kinases in combination with MEK inhibitors may be more effective than the utilization of small molecule inhibitors to both pathways (Table 3) (Jokinen & Koivunen 2015). In addition to the advantages of silencing key players of the PI3K pathway, previous studies have also demonstrated that siRNAs can be adapted to specifically silence point mutations (Fleming et al. 2005). In fact, silencing mutant KRAS as a therapeutic strategy in the treatment of pancreatic cancer has been associated with clinical success (Table 2). As PIK3CA mutations are prevalent in TNBCs (Shah et al. 2012), preferential siRNA depletion of mutant gene expression is desirable, because this strategy is equipped to eliminate dose-limiting toxicities associated with PI3K inhibitors (Table 3). Collectively, these ideas suggest that an siRNA approach to silencing the PI3K pathway may be an effective therapeutic strategy in combination with chemotherapy because of its versatile effects in downregulating PI3K (1) kinase activity, (2) scaffolding activity and (3) mutations.

### Table 3 siRNA nanoparticle strategies to augment proposed TNBC subtype-specific therapies.

<table>
<thead>
<tr>
<th>TNBC subtype</th>
<th>Current proposed therapy</th>
<th>Proposed siRNA nanoparticle strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal-like</td>
<td>Cisplatin</td>
<td>siBRCA + cisplatin</td>
</tr>
<tr>
<td>Mesenchymal</td>
<td>PI3K/mTOR inhibitor</td>
<td>sip110b + MEK inhibitor</td>
</tr>
<tr>
<td>Luminal androgen receptor</td>
<td>Bicalutamide</td>
<td>siPI3KCA mutant + chemo</td>
</tr>
<tr>
<td></td>
<td></td>
<td>siGF combination</td>
</tr>
<tr>
<td></td>
<td></td>
<td>siEMT combination</td>
</tr>
</tbody>
</table>

AR, androgen receptor; EMT, epithelial-mesenchymal transition; GF, growth factor.
Alternatively, as TNBCs characterized by the M subtype also harbor elevated growth factor signaling, inhibition of growth factor pathways is also a viable therapeutic strategy. In fact, elevated EGFR expression is reported in up to 76% of TNBC patients (Martin et al. 2012), although inconsistent percentages are reported depending on the method of EGFR detection (Nakai et al. 2016). Current clinical trials have explored small molecule EGFR inhibitors and anti-EGFR monoclonal antibodies as single agents and in combination with chemotherapy (Nakai et al. 2016). Unfortunately, these trials have been disappointing, owing to the activation of alternative signaling pathways that mediate resistance (Nakai et al. 2016). siRNA nanoparticle silencing of a combination of growth factors may present as a feasible approach to circumvent current resistance mechanisms (Table 3), and future studies need to determine what combinations would be most efficacious. Similarly, as mesenchymal subtypes of TNBCs are also characterized with an increase in EMT gene signature, siRNA nanoparticle strategies to silence a combination of EMT transcription factors also present as a feasible therapeutic strategy (Table 3).

In summary, utilization of siRNA nanoparticles as a therapeutic strategy to inhibit PI3K/mTOR, growth factor and EMT pathways represents an attractive solution to challenges that are associated with the use of available small molecule PI3K/mTOR inhibitors. Because functional inhibition of a target using small molecule inhibitors vs using siRNA strategies can have significantly different outcomes (Weiss et al. 2007), future studies need to clearly define what these differences are and which approach exerts the maximal therapeutic efficacy, while limiting toxicities. Future studies should also determine whether delivery of point-mutated siRNA can exert miRNA-like functions on the corresponding WT gene.

**Luminal androgen receptor expressing TNBCs and bicalutamide**

The LAR subtype exhibits elevated androgen receptor (AR) signaling and TNBC cell lines of this subtype preferentially respond to bicalutamide, an AR inhibitor. Approximately 10–43% of TNBCs express AR; however, the prognostic value of AR currently remains controversial (Pietri et al. 2016). Indeed, some studies have demonstrated that AR expression is correlated to increased mortality (Hu et al. 2011), increased tumor stage and increased lymph node metastasis (McGhan et al. 2014), whereas others have shown that AR-expressing TNBCs have decreased lymph node metastasis (Rakha et al. 2007), decreased tumor burden (Luo et al. 2010, Park et al. 2011) and increased overall survival (Luo et al. 2010). The reasons behind these contradictory results are currently unclear, although it is possible that differences in scoring systems and utilized reagents could have contributed (McGhan et al. 2014). Recently, a phase 2 clinical trial with 26 patients harboring AR-positive and ER/PR-negative breast cancers demonstrated that approximately 19% of patients who received bicalutamide exhibited a 6-month clinical benefit (Gucalp et al. 2013). These results suggest that some patients clearly benefit from AR antagonists and further testing of next-generation AR-targeting agents, including enzalutamide and CYP17 inhibitors are under way (Gucalp et al. 2013). siRNA nanoparticles silencing AR have not been evaluated in the context of TNBCs. Lessons from treating prostate cancer patients with bicalutamide indicate that mutations in the hormone-binding pocket of AR can switch anti-androgen antagonists to gaining agonist functions, thereby driving drug resistance (Tian et al. 2015). It is tempting to speculate that siRNA silencing of AR could circumvent these limitations (Table 3). Future studies need to fully investigate which subsets of AR-expressing TNBC patients will benefit from AR-targeted therapies.

**TNBCs harboring stromal signatures**

Recently, the aforementioned six subtypes of TNBCs have been refined to four distinct transcriptional subtypes with differing clinical characteristics (Lehmann et al. 2016). These include the BL1, BL2, M and LAR subtypes, whereas the previously stratified MSL and IM subtypes are now descriptors that indicate the presence of stromal and immune cell within the primary tumor (Lehmann et al. 2016). Indeed, Lehmann and coworkers demonstrated that tumor subtypes changed to MSL when the matched stromal cells were included, suggesting that the MSL gene expression pattern is a characteristic of stromal cells (Lehmann et al. 2016). Prior to the refined 4 transcriptional subtype classification system, MSL TNBC cell lines exhibited in vitro sensitivity to dasatinib, a broad-spectrum tyrosine kinase inhibitor that targets SRC family kinases (Lehmann et al. 2011). Not surprisingly, a phase 2 clinical trial evaluating dasatinib for the treatment of TNBC demonstrated only limited activity, and combinations with chemotherapies were subsequently explored (Finn et al. 2011). Dasatinib is synergistic when treated in combination with cetuximab and cisplatin in vitro (Kim et al. 2013). However, dasatinib treatment also exerts immunosuppressive effects (Blake et al. 2008,
Table 4  Proposed therapeutic strategies using siRNA nanoparticles to address stromal and immune cells within the primary tumor.

<table>
<thead>
<tr>
<th>TNBC descriptor</th>
<th>Proposed siRNA nanoparticle strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesenchymal stem-like Immunomodulatory</td>
<td>siRNA against stromal cells siPD1/siPD-L1</td>
</tr>
</tbody>
</table>

Fraser et al. (2009), which may offset the effects of antitumor immunity. More recently, a nanoparticle formulation of dasatinib has been utilized in combination with the anti-microtubule chemotherapy, vincristine, and results indicate (1) enhanced tumor cell uptake of dasatinib, (2) increased apoptosis and (3) decreased vascular mimicry channels (Zeng et al. 2015). Whether or not nanoparticle delivery of anti-SRC siRNA can recapitulate the effects of liposomal dasatinib is unclear. However, the refinement of utilizing MSL as a description to highlight the presence of stromal cells in the microenvironment points at the possibility of utilizing siRNA nanoparticles to target not only tumor cells but also stromal cells that function in creating a supportive tumor microenvironment (Table 4). Future studies need to determine appropriate therapeutic targets for both the tumor epithelial and stromal components and localization strategies.

TNBCs harboring immune infiltration

Interestingly, approximately 20% of TNBCs are highly enriched for immune cell infiltration, which is (1) an indicator of good prognosis, (2) a predictor of improved relapse-free survival (Lehmann et al. 2016) and pathological complete response (pCR) and (3) suggestive that immunotherapy may be a good therapeutic option (Garcia-Teijido et al. 2016). Importantly, the anti-PD-1 immune checkpoint inhibiting monoclonal antibody, pembrolizumab, has recently demonstrated clinical activity in a phase 1b clinical trial for the treatment of PD-L1-positive, heavily pretreated, metastatic TNBCs (Nanda et al. 2016). These preliminary studies demonstrate an overall response rate of 18.5%, and a phase 2 clinical trial is underway. This overall response rate suggests that a subset of patients may be resistant to pembrolizumab and its incorporation for clinical use is currently unclear. Potential mechanisms of pembrolizumab resistance may involve (1) conformational changes or co-receptor expression that shields the therapeutic target from drug binding, (2) upregulation of alternative receptors that cooperate to induce hyperactivation of the therapeutic target, (3) activation of downstream effectors that bypass the inhibitory effects of the drug and (4) mutation and constitutive activation of the therapeutic target. Whether or not pembrolizumab resistance actually involves these hypothetical resistance mechanisms is unclear. Interestingly, nanoparticle delivery of anti-HER2 siRNA has been demonstrated to circumvent resistance mechanisms associated with trastuzumab, a humanized monoclonal antibody used for treating HER2 breast cancers (Gu et al. 2016). It is tempting to speculate that silencing PD-1 or PD-L1 expression by siRNA nanoparticles may circumvent pembrolizumab resistance (Table 4); however, further testing, including initial studies to determine if siRNA nanoparticles can be adapted to specifically target PD-1 expression on lymphocytes are required.

Ongoing challenges associated with the clinical use of siRNA nanoparticles

Even though preclinical studies and recent clinical trials have established siRNA nanoparticles as a promising therapeutic strategy for cancer treatment, a number of ongoing challenges have limited the technology. First, the percentage of siRNA nanoparticles that are actually taken up by tumor cells is estimated to be only 0.7% of the injected dose (Wilhelm et al. 2016). Active targeting strategies such as those summarized in Table 1 improves nanoparticle uptake to ~0.9%; however, 0.9% of the injected dose still represents a miniscule amount. Although synthesizing sufficient nanoparticles for preclinical mouse models are not limited by these low uptake statistics (the average mouse is 20 g), scaling these amounts up for applicability in humans may cause additional complications. Synthesis of nanoparticles in larger amounts may compromise function of the nanoparticles, for example, through aggregation (Wilhelm et al. 2016). The cost associated with the synthesis and quality control could be prohibitively high. Additionally, the large volume of nanoparticles administered into a patient could introduce additional technical challenges and issues with immunity. Lastly, because approximately 99% of the nanoparticles are not taken up by tumor cells, off-target effects may pose serious restrictions. However, the good news is that siRNA silencing of target genes by nanoparticles is a reversible process, and withdrawal of the nanoparticle should reverse potential side effects. Future studies need to clearly dissect the mechanisms of nanoparticle localization and uptake by tumor cells to exploit potential pathways that can improve tumor-specific accumulation.
Conclusion

The success of using siRNA as a tool to dissect molecular pathways has prompted researchers to explore its potential as a therapeutic platform. Indeed, over the past decade, various siRNA nanoparticle strategies have been employed to treat solid tumors in clinical trials. Completed trials have demonstrated both lipid and polymer siRNA nanoparticles to be safe and effective for silencing target gene expression, and preliminary results indicate good therapeutic outcomes in a variety of cancers. These clinical studies have laid a solid foundation for the use of siRNA nanoparticles to address ongoing challenges in cancer treatment, such as the case for TNBC. There is currently a lack of effective FDA-approved targeted therapies for the treatment of TNBCs. Recent studies using high-throughput sequencing has revealed the diverse genetic heterogeneity of TNBC that may underlie the difficulty associated with designing an appropriate targeted therapy for the treatment of this disease. Various ongoing clinical trials are now evaluating TNBC treatment regimens based on distinct molecular characteristics, such as BRCA and LAR. Because TNBC is characterized by a heterogenous genetic landscape, the versatility of selectively targeting different genes by siRNA nanoparticles makes this technology an attractive therapeutic option for TNBC treatment. Various preclinical studies utilizing siRNA nanoparticles to target (1) components of the cell cycle, (2) factors that induce EMT and (3) factors that reduce chemotherapy efficacy have been demonstrated to inhibit TNBC disease progression in mouse models. siRNA nanoparticles may be further adapted to complement proposed therapeutic strategies associated with the recently identified TNBC subtypes. Many of these proposed strategies are currently being tested in clinical trials and the use of siRNA nanoparticles to complement them may further strengthen their therapeutic efficacy. Collectively, siRNA nanotechnology is a promising solution in eliminating the roadblocks to successful development of a targeted therapy for TNBC treatment.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Acknowledgements

Members of the Jackson Laboratory are thanked for providing helpful comments and suggestions.

References


Received in final form 23 January 2017
Accepted 1 February 2017
Accepted Preprint published online 1 February 2017